Advisor Group’s Teva Pharmaceuticals TEVA Stock Holding History

Advisor Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$442K	Sell	45,080 -8,559	-16%	-$76.4K	﹤0.01%	1762
2019 Q3	$368K	Buy	53,639 +2,264	+4%	+$17.3K	﹤0.01%	1837
2019 Q2	$473K	Buy	51,375 +2,101	+4%	+$25.3K	﹤0.01%	1656
2019 Q1	$773K	Sell	49,274 -5,948	-11%	-$105K	0.01%	1275
2018 Q4	$851K	Buy	55,222 +5,281	+11%	+$108K	0.01%	1039
2018 Q3	$1.08M	Buy	49,941 +24,473	+96%	+$568K	0.01%	940
2018 Q2	$620K	Sell	25,468 -1,881	-7%	-$38.4K	0.01%	1163
2018 Q1	$467K	Buy	27,349 +1,748	+7%	+$34.1K	0.01%	1373
2017 Q4	$484K	Sell	25,601 -7,120	-22%	-$107K	0.01%	1348
2017 Q3	$576K	Buy	32,721 +8,171	+33%	+$184K	0.01%	1110
2017 Q2	$816K	Buy	24,550 +6,067	+33%	+$188K	0.01%	857
2017 Q1	$593K	Buy	18,483 +5,106	+38%	+$174K	0.01%	973
2016 Q4	$485K	Sell	13,377 -3,331	-20%	-$133K	0.01%	1036
2016 Q3	$769K	Buy	16,708 +665	+4%	+$34.7K	0.02%	748
2016 Q2	$803K	Buy	+16,043	New	+$854K	0.02%	700

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Advisor Group's TEVA Position: Q4 2019 in Review

Advisor Group reduced its Teva Pharmaceuticals (TEVA) stake by 16% in Q4 2019, selling an estimated $76.4K and leaving 45,080 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #1762.

Advisor Group first reported a position in TEVA in Q2 2016 and has held it in 15 quarters since. The position peaked at $1.08M in Q3 2018. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

Advisor Group held 45,080 shares of Teva Pharmaceuticals worth $442K as of Q4 2019.
Advisor Group sold 8,559 Teva Pharmaceuticals shares in Q4 2019, an estimated $76.4K.
Teva Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #1762 holding.
Advisor Group first reported a position in Teva Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
Advisor Group's Teva Pharmaceuticals position peaked at $1.08M in Q3 2018.
436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.